Horton J
Cancer. 1984 Feb 1;53(3 Suppl):790-7. doi: 10.1002/1097-0142(19840201)53:3+<790::aid-cncr2820531330>3.0.co;2-f.
Follow-up of patients with breast cancer is often pursued in an irregular, haphazard, and costly way. For patients who have had potentially curative treatment for localized breast cancer, effort should be concentrated for the life time of the patient on early detection of persistent or new breast cancers, and early detection of endometrial and large bowel cancers in order to maximize the chance of cure. The patient-physician interaction is the dominant factor in such follow-up. Bone and other scans and carcinoembryonic antigen levels do not detect curable disease, so these are not indicated for routine follow-up of patients with early stage disease. For patients with metastasis, follow-up has a different emphasis and is geared to defining the extent and activity of metastasis and early detection of treatable complications so as to optimize palliation. For all patients it is necessary to continually evaluate their social and emotional requirements and to evaluate the family for risk of cancer and other problems. A follow-up team, led by the physician, is required to best fulfill these multiple needs.
乳腺癌患者的随访往往以不规律、随意且昂贵的方式进行。对于接受过局限性乳腺癌潜在治愈性治疗的患者，应在患者的一生中集中精力，尽早发现持续性或新发乳腺癌，以及尽早发现子宫内膜癌和大肠癌，以最大程度提高治愈几率。医患互动是此类随访中的主导因素。骨骼及其他扫描以及癌胚抗原水平无法检测出可治愈的疾病，因此对于早期疾病患者的常规随访并不建议进行这些检查。对于有转移的患者，随访有不同的重点，旨在确定转移的范围和活性，并尽早发现可治疗的并发症，以优化姑息治疗。对于所有患者，有必要持续评估他们的社会和情感需求，并评估其家族患癌风险及其他问题。需要一个由医生领导的随访团队来最好地满足这些多方面的需求。
